Spectrum Launches Trial of SPI-153 in Hormone-Dependent Prostate Cancer

Spectrum Pharmaceuticals has announced the launch of a Phase II trial to evaluate the safety and efficacy of SPI-153 as a treatment for patients with hormone-dependent prostate cancer.

The multicenter Phase II trial is designed to evaluate the effects of SPI-153 on hormonal levels, in particular testosterone, as well as objective antitumor effects. The trial will be conducted in Europe with the collaboration of AEterna Zentaris